Beximco Pharmaceuticals (LSE:BXP) Cash Flow for Dividends: £-1.3 Mil (TTM As of Mar. 2026)


LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
67 GF Score
Price £0.50
GF Value £0.45
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Cash Flow for Dividends?

Beximco Pharmaceuticals LSE:BXP 67 Cash Flow for Dividends is £-1.3 Mil as of Mar. 2026. GuruFocus rates LSE:BXP with a GF Score™ of 67/100 and a GF Value™ of £0.45 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Beximco Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was £-0.2 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was £-1.3 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Beximco Pharmaceuticals's quarterly payment of dividends declined from Sep. 2025 (£-1.0 Mil) to Dec. 2025 (£-0.1 Mil) but then increased from Dec. 2025 (£-0.1 Mil) to Mar. 2026 (£-0.2 Mil).

Beximco Pharmaceuticals's annual payment of dividends increased from Jun. 2023 (£-9.4 Mil) to Jun. 2024 (£-9.5 Mil) and increased from Jun. 2024 (£-9.5 Mil) to Jun. 2025 (£-9.6 Mil).

Beximco Pharmaceuticals Cash Flow for Dividends Related Terms

Beximco Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Cash Flow for Dividends Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.48 -9.76 -9.42 -9.53 -9.64

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.57 -0.06 -0.99 -0.05 -0.18
LSE:BXP
67GF Score
Beximco Pharmaceuticals PLC LSE:BXP
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £-1.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of £-1.3 Mil mean?
Beximco Pharmaceuticals (LSE:BXP) has a Cash Flow for Dividends of £-1.3 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Cash Flow for Dividends too high?
Beximco Pharmaceuticals' current Cash Flow for Dividends is £-1.3 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cash Flow for Dividends compare to ZTS and UTHR?
Beximco Pharmaceuticals' Cash Flow for Dividends of £-1.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Cash Flow for Dividends is £-1.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.45, compared to a current price of £0.50 — trading 11.1% above its estimated fair value. The current Cash Flow for Dividends is £-1.3 Mil. Beximco Pharmaceuticals' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Cash Flow for Dividends is £-1.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.50 is trading 11.1% above its estimated GF Value™ of £0.45. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LSE:BXP:

  • Cash Flow for Dividends: £-1.3 Mil
  • GF Value™: £0.45 vs. price of £0.50 (11.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
67GF Score

Get the complete analysis for LSE:BXP

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.50
Price
£0.45
GF Value